Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,068 across all filing types
Latest filing 2022-01-19 AGM Information
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB". It details the date, time, location, procedures for attendance (in person, proxy, or postal voting), agenda items (including a proposed name change and a resolution on a rights issue), and voting requirements for an upcoming general meeting. This content directly corresponds to the purpose of soliciting shareholder votes and providing necessary pre-meeting information, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI). Although it relates to a general meeting, it is the notice/solicitation document itself, not the final voting results (DVA) or general AGM presentation materials (AGM-R).
2022-01-19 English
OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION
Capital/Financing Update Classification · 98% confidence The document explicitly details a resolution by the Board of Directors to conduct a 'new issue of shares with preferential rights' amounting to approximately SEK 151 million. This action involves setting subscription prices, record dates, subscription periods, and discussing shareholder dilution and guarantee commitments. These elements are characteristic of a corporate action related to raising capital or changing the capital structure. The most fitting category among the provided definitions is 'Capital/Financing Update' (CAP). Although it mentions a prospectus will be published later (suggesting an RPA might be involved if this were just the announcement), the core content is the detailed plan and terms of the financing itself, making CAP the primary classification.
2022-01-19 English
OASMIA BESLUTAR OM EN FULLT SÄKERSTÄLLD FÖRETRÄDESEMISSION OM CIRKA 151 MILJONER KRONOR
Capital/Financing Update Classification · 98% confidence The document is a detailed announcement in Swedish regarding a fully secured rights issue ("Företrädesemission") proposed by Oasmia Pharmaceutical AB to raise approximately 151 million SEK. It outlines the terms (subscription price, ratio, subscription period), the purpose (financing continued development), shareholder rights, and guarantees provided by major shareholders and external investors. This content directly relates to fundraising, capital structure changes, and the issuance of new shares/rights. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions a prospectus will be published later, the core of this document is the announcement and details of the capital raising event itself, not just the announcement of the report (RPA) or a general regulatory filing (RNS).
2022-01-19 Swedish
Valberedning utsedd inför Oasmias årsstämma 2022
AGM Information Classification · 95% confidence The document is a short announcement dated December 2, 2021, regarding the appointment of the Nomination Committee (Valberedning) for Oasmia Pharmaceutical AB's Annual General Meeting (AGM) scheduled for May 25, 2022. It details the committee members and provides contact information. Since it is a specific announcement related to the upcoming AGM and the composition of its preparatory committee, it aligns best with the 'AGM Information' category, which covers presentations and materials shared during the AGM, or related preparatory announcements. Given the options, AGM-R is the most appropriate fit for a formal announcement concerning the AGM's structure and proceedings, even if it precedes the meeting itself. It is not a full report (10-K, IR), a proxy statement (PSI), or a general regulatory filing (RNS), as it is highly specific to the AGM process.
2021-12-02 Swedish
Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia
AGM Information Classification · 98% confidence The document explicitly announces the appointment of the Nomination Committee for the upcoming 2022 Annual General Meeting (AGM). It details the members appointed based on the ownership structure and provides the date of the AGM. This content directly relates to the preparatory and administrative aspects surrounding the AGM, fitting the definition of 'AGM Information' (AGM-R), which covers presentations and materials shared during the AGM, or related preparatory announcements. Since it is an announcement about the committee structure for the AGM, AGM-R is the most precise fit over general regulatory filings.
2021-12-02 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Oasmia Pharmaceutical AB covering the period from January 1 to September 30, 2021. It contains detailed financial statements, including net sales, operating results, and earnings per share for both the third quarter and the nine-month period. It also includes management commentary, business updates, and strategic outlooks. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2021
2021-11-18 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.